New Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the anticoagulant medicine Apixaban in Canada

We at Tiefenbacher Pharmaceuticals are driven by enabling people around the world a better access to more affordable high-quality medicines. That´s why we are happy to share that we have successfully prepared the launch of the generic version of Apixaban for an early market entry in Canada.
Apixaban is an oral anticoagulant (blood thinner) indicated for the prevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with atrial fibrillation, and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of their recurrence.
The 2,5 mg and 5 mg tablets have been developed in Tiefenbacher Group´s own laboratories in India and will be marketed in Canada by our cooperation partner, one of the biggest generic pharmaceutical companies in the world. A launch in further international markets will follow. With this early market entry Tiefenbacher Pharmaceuticals achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.  

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).  

For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or please visit us on:www.tiefenbacher-pharmaceuticals.com

 

About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on:  www.tiefenbachergroup.com